Search results
Order by most recent / most popular / relevance
Results: 1-3 of 3
FTC gets shut down - once again - in its bid to change how courts view reverse payment settlements
- Sheppard Mullin Richter & Hampton LLP
- -
- USA
- -
- June 3 2010
As previously reported on this blog, in January 2009, the Federal Trade Commission launched its latest challenge to the legality of reverse payment settlements in the pharmaceutical industry, this time directed at two settlements involving the brand-name drug AndroGel
The FTC's latest remarks in opposition to reverse payment settlements: banning them would save consumers $35 billion
- Sheppard Mullin Richter & Hampton LLP
- -
- USA
- -
- July 9 2009
The Federal Trade Commission's Chairman, Jon Leibowitz, continued the FTC's aggressive campaign against reverse payment settlements (also called "pay-for-delay" or "exclusion" settlements) by delivering a speech at the Center for American Progress entitled "'Pay-for Delay' Settlements in the Pharmaceutical Industry: How Congress Can Stop Anticompetitive Conduct, Protect Consumers' Wallets, and Help Pay for Health Care Reform (The $35 Billion Solution)" (June 23, 2009
The latest advance in the debate over reverse payment settlements: will the Supreme Court punt, again?
- Sheppard Mullin Richter & Hampton LLP
- -
- USA
- -
- June 12 2009
On April 24, 2009, a group of professors of law, economics and business, together with the American Antitrust Institute, the Public Patent Foundation, and AARP (collectively "amici") filed an amicus brief urging the Supreme Court to grant certiorari and reverse the decision of the Federal Circuit Court of Appeals in In re Cirpoflaxacin Hydrochloride Antitrust Litigation, 544 F.3d 1323 (Fed. Cir. 2008) ("Cipro"
Current Search
- Workarea - Intellectual Property
- Author - Helen Cho Eckert